secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2026-08-12T20:08:26+00:00
Accession:  0001437749-26-027311
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Talphera Q2 2026 net loss $4.3M; nafamostat CRRT study 75% enrolled
-------------------------------------------------------------------

- Net loss $4.3M ($0.06/share) vs $3.5M loss ($0.10/share) in Q2 2025; cash/investments $17.1M at June 30, 2026.
- R&D and SG&A expenses combined $3.9M vs $3.7M in Q2 2025, driven by higher Niyad development costs.
- NEPHRO CRRT study of nafamostat 75% enrolled, expected to complete in 2026; all target clinical sites activated.
- KDIGO 2026 draft guidelines cite nafamostat as acceptable CRRT anticoagulant; updated market research estimates 200k annual U.S. CRRT procedures (+21%).
- Regained Nasdaq compliance with $1 bid price rule.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774926027311/0001437749-26-027311-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774926027311/acrx20260811_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-027311

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer